Vaxess Technologies, Inc.

Vaxess Technologies is a venture-backed biotechnology company developing novel products based on its proprietary MIMIX microneedle delivery platform. Our lead program is a sustain-release flu microneedle patch. We also have a pipeline of undisclosed targets including mRNA, immun/ooncology and other in-house targets and in partnership with several pharmaceutical companies.

Vaxess is commercializing a proprietary technology that uses a silk-derived protein to stabilize vaccines so they can be stored and shipped without refrigeration. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world.

Proprietary Silk Protein Technology -- Fibroin, a protein found in native silk fibers, has unique properties that enable stabilization of biological compounds. Research & Development at Vaxess is cross-disciplinary, integrating aspects of chemistry, biology, immunology, biomedical and chemical engineering, and covers a wide range of product targets.